Rational Design of Non-Nucleoside, Potent, and Orally Bioavailable Adenosine Deaminase Inhibitors: Predicting Enzyme Conformational Change and Metabolism

This publication has 14 references indexed in Scilit:

• 5-Oxatricyclo[5.1.0.0^1,3]octan-4-one, containing an enantiomorph and a racemate and not two polymorphs, is another example of a composite crystal
  Acta crystallographica Section B, Structural science, crystal engineering and materials, 2003
• Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment
  Cancer Chemotherapy and Pharmacology, 2002
• Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage
  Nature, 2001
• Adenosine deaminase: Functional implications and different classes of inhibitors
  Medicinal Research Reviews, 2001
• Adenosine Deaminase Inhibitors: Synthesis and Biological Evaluation of Unsaturated, Aromatic, and Oxo Derivatives of (+)-erythro-9-(2‘S-Hydroxy-3‘R-nonyl)adenine [(+)-EHNA]
  Journal of Medicinal Chemistry, 2000
• SCID: The role of adenosine deaminase deficiency
  Immunology Today, 1997
• Direct Association of Adenosine Deaminase with a T Cell Activation Antigen, CD26
  Science, 1993
• Synthesis of enantiomerically pure muscarine analogs
  Tetrahedron Letters, 1990
• Effect of chirality in erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) on adenosine deaminase inhibition
  Biochemical Pharmacology, 1982
• Pharmacokinetics of inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl)adenine in CBA mice
  Biochemical Pharmacology, 1982